%D8%A8%D9%8A%D8%BA%D9%86%D8%AA%D9%8A%D8%B1%D9%81%D9%8A%D8%B1%D9%88%D9%86_%E2%80%93_%D8%A3%D9%84%D9%81%D8%A7_%E2%80%93_2%D8%A8Peginterferon_alfa-2bPeginterfer%C3%B3n_alfa-2bPeginterf%C3%A9ron_alfa-2b%D5%8A%D5%A5%D5%A3%D5%AB%D5%AC%D5%A1%D6%81%D5%BE%D5%A1%D5%AE_%D5%AB%D5%B6%D5%BF%D5%A5%D6%80%D6%86%D5%A5%D6%80%D5%B8%D5%B6_%D5%A1%D5%AC%D6%86%D5%A1-2bPeginterferon_alfa-2b%E0%AC%AA%E0%AD%87%E0%AC%9C%E0%AC%BF%E0%AC%A3%E0%AD%8D%E0%AC%9F%E0%AC%B0%E0%AC%AB%E0%AD%87%E0%AC%B0%E0%AC%A8_%E0%AC%86%E0%AC%B2%E0%AC%AB%E0%AC%BE-%E0%AD%A8%E0%AC%AC%E0%AC%BFPeginterferon_alfa-2bPegilirani_interferon_alfa-2bPegilirani_interferon_alfa-2b%D0%9F%D0%B5%D0%B3%D1%96%D0%BB%D1%8C%D0%BE%D0%B2%D0%B0%D0%BD%D0%B8%D0%B9_%D1%96%D0%BD%D1%82%D0%B5%D1%80%D1%84%D0%B5%D1%80%D0%BE%D0%BD_%D0%B0%D0%BB%D1%8C%D1%84%D0%B0-2bPeginterferon_alfa-2bQ7160789
about
Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By SurgeryStudy of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients.Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis CTaribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder SubjectsPegintron Induction Therapy in HCV Non-RespondersEXtended Therapy in Hepatitis C Genotype 3 Infected PatientsPROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2bPROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2bEfficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected PatientsEfficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected PatientsTreating Hispanic Patients Diagnosed With Hepatitis C Using BoceprevirAdjuvant PEG Intron in Ulcerated MelanomaBoceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis CPegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid LeukaemiaStudy of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4Pilot Study of IFN α2b for Melanoma PatientsPhase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCVQuality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide VaccineTo Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube CancerRe-treatment of HCV Following DAA FailureEfficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)Yervoy With Sylatron Unresectable Stage 3 or 4 MelanomaThe Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIVGrazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) InfectionA Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin
P4844
Q61864788-C413ADEA-4D80-41F4-86FF-A536E52AAA3EQ61917768-0444D299-8FF7-47B2-9AFD-00F4EEDA5EF4Q61921656-003B9865-3596-4CB0-A810-5843D4BDD61FQ61921676-D4306695-5CAE-4856-A83A-71F173485FC3Q61921745-7342D9BF-FE5A-417C-9BFF-0804C6246210Q61922228-CB10739C-E35D-488D-B1F2-58F31A413F45Q61924468-63068046-37BB-4346-9E7D-8DBDC63FCAE5Q61933098-D99F6A24-CD60-4498-810D-06ECDAE741DFQ61933814-1D01A77E-27B0-4BD8-B210-9EEFBE19682BQ61934712-46CC691C-B13C-4626-9DAE-09217A7A8B2FQ61936662-E99755C0-3153-44DF-A681-588F6569BF41Q61939209-C71212E9-95E8-49D3-8453-1D2FD09FD0E4Q61939210-D6E2E0FA-66B8-47B3-A25A-92A66352CA8BQ61955958-BA8CCDB7-DCD0-49C2-A8A3-010DB25FD386Q61956384-21A5E4A8-22EB-4290-947E-9D9E8C5FD63BQ61956553-976A1527-ED4C-4097-BD58-86CF77269FD9Q61957476-8E9EDB1F-ACE1-4DDE-A05E-110187594BDDQ61965920-D6C91982-8B05-404F-A40C-83E9B60705B8Q61967915-2E8879A3-D507-4B5E-8FD0-6BC8437DA0ABQ61969182-A58D48A3-F907-40BD-93BB-0D0BDA945778Q61979140-390250D6-A616-47A8-8062-CAC75BB2D177Q61980276-12C49C27-1AEB-4645-AFD9-F0118C80F16BQ61980557-24DF9353-8F6D-45B1-A36F-3A5FA47D8F97Q61981259-C086AB47-BDE9-49F7-BF8D-3F2CE4704B07Q61981270-AC4E9604-57AC-4E29-9AB3-9AB9FB87E47CQ61981410-5ADFD6E0-7880-4345-B368-385A04574AD8Q62031237-6935AB61-C45F-46E5-9777-6CFEE3A23002Q62105909-A9FA85BB-53EE-46D5-B123-4B1589B1BCE7Q62110392-83A275C9-F268-405A-A44F-CA9E51C626E3Q62110692-E0452257-362A-4EBC-9663-73D0B8AFE08AQ62810095-7AA4CC90-5EDA-476B-8596-2B2F9145E9ECQ62813641-9D48EC36-D289-4F45-A279-EBBD057BA6C7Q63063343-CCB01415-2ADA-4484-88E8-CC479DBE3D60Q63318997-3686B2FA-93CE-4A40-B92D-96EA0B5A6ECFQ63321387-50993E9A-95F4-4EC3-AEDF-52B7C032676DQ63321910-9C69ED02-4FBF-4F3F-84CD-E6F05FD0C76DQ63322474-1B6A4040-BCBB-4B4A-8CD4-01E390815367Q63333538-DF04FBA0-0B62-4616-8F16-4993C1707C5AQ63334274-F6DB2F5A-E14C-4570-9F62-36CE889CDDA6Q63336194-410FFF19-52D0-46F7-8ACA-4EDAFC3FBA97
P4844
description
chemická sloučenina
@cs
chemische Verbindung
@de
chemische verbinding
@nl
component quimic
@oc
compost químic
@ca
composto chimico
@it
composto químico
@gl
composto químico
@pt
composto químico
@pt-br
composé chimique
@fr
name
Pegilirani interferon alfa-2b
@sh
Pegilirani interferon alfa-2b
@sr
Peginterferon alfa-2b
@en
Peginterferon alfa-2b
@id
Peginterferon alfa-2b
@pl
Peginterferon alfa-2b
@vi
Peginterferón alfa-2b
@es
peginterféron alfa-2b
@fr
πεγκιντερφερόνη άλφα-2β
@el
Пегільований інтерферон альфа-2b
@uk
type
label
Pegilirani interferon alfa-2b
@sh
Pegilirani interferon alfa-2b
@sr
Peginterferon alfa-2b
@en
Peginterferon alfa-2b
@id
Peginterferon alfa-2b
@pl
Peginterferon alfa-2b
@vi
Peginterferón alfa-2b
@es
peginterféron alfa-2b
@fr
πεγκιντερφερόνη άλφα-2β
@el
Пегільований інтерферон альфа-2b
@uk
altLabel
C860H1353N229O255S9
@sr
PEG-interferon alfa-2b
@sr
Peg Intron
@sr
Peg-Intron
@en
Peginterferon alfa-2b
@sr
بيغنتيرفيرون – ألفا – ٢ب
@ar
ପେଜିଣ୍ଟ୍ରନ
@or
prefLabel
Pegilirani interferon alfa-2b
@sh
Pegilirani interferon alfa-2b
@sr
Peginterferon alfa-2b
@en
Peginterferon alfa-2b
@id
Peginterferon alfa-2b
@pl
Peginterferon alfa-2b
@vi
Peginterferón alfa-2b
@es
peginterféron alfa-2b
@fr
πεγκιντερφερόνη άλφα-2β
@el
Пегільований інтерферон альфа-2b
@uk
P2175
P31
P486
P592
P6366
P665
P2115
N0000148697
N0000178331
P2275
Peginterferon alfa-2b
@en
P231
215647-85-1
P232
P2566
100.208.164
P267
P2868
P3345
P486
P592
CHEMBL1201561
P6366
2780998412
P652
G8RGG88B68